The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment
-
Published:2024-05
Issue:
Volume:132
Page:111944
-
ISSN:1567-5769
-
Container-title:International Immunopharmacology
-
language:en
-
Short-container-title:International Immunopharmacology
Author:
Li Yaxian,
Zheng YuejiangORCID,
Xu Shuyi,
Hu Hai,
Peng Liyun,
Zhu Jianwei,
Wu MingyuanORCID
Reference54 articles.
1. Pancreatic cancer stroma: an update on therapeutic targeting strategies;Hosein;Nat. Rev. Gastroenterol. Hepatol.,2020
2. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020
3. The dark side of immunotherapy: pancreatic cancer;Mucciolo;Cancer Drug Resist.,2020
4. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N. Engl. J. Med.,2019
5. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial;Goldman;Lancet Oncol.,2021